LLY — Eli Lilly and Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual cashflow statement for Eli Lilly and Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	C2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	6,194	5,582	6,245	5,240	10,590
Depreciation
Deferred Taxes
Non-Cash Items	-136	1,956	2,004	2,868	4,529
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-747	-1,023	-0.8	-3,055	-5,385
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Taxes Payable
Cash from Operating Activities	6,500	7,261	7,586	4,240	8,818
Capital Expenditures	-2,029	-1,873	-2,985	-7,392	-8,404
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-230	-889	-778	239	-898
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities	-2,259	-2,762	-3,763	-7,153	-9,302
Financing Cash Flow Items	-242	-296	-309	-335	-491
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-3,137	-4,131	-5,407	3,496	1,230
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	1,320	161	-1,752	752	450